Literature DB >> 33650031

Dihydroquinazolin-4(1H)-one derivatives as novel and potential leads for diabetic management.

Oluwatoyin Babatunde1,2, Shehryar Hameed1, Uzma Salar3, Sridevi Chigurupati4, Abdul Wadood5, Ashfaq Ur Rehman5, Vijayan Venugopal6, Khalid Mohammed Khan7,8, Muhammad Taha9, Shahnaz Perveen10.   

Abstract

A variety of dihydroquinazolin-4(1H)-one derivatives (1-37) were synthesized via "one-pot" three-component reaction scheme by treating aniline and different aromatic aldehydes with isatoic anhydride in the presence of acetic acid. Chemical structures of compounds were deduced by different spectroscopic techniques including EI-MS, HREI-MS, 1H-, and 13C-NMR. Compounds were subjected to α-amylase and α-glucosidase inhibitory activities. A number of derivatives exhibited significant to moderate inhibition potential against α-amylase (IC50 = 23.33 ± 0.02-88.65 ± 0.23 μM) and α-glucosidase (IC50 = 25.01 ± 0.12-89.99 ± 0.09 μM) enzymes, respectively. Results were compared with the standard acarbose (IC50 = 17.08 ± 0.07 μM for α-amylase and IC50 = 17.67 ± 0.09 μM for α-glucosidase). Structure-activity relationship (SAR) was rationalized by analyzing the substituents effects on inhibitory potential. Kinetic studies were implemented to find the mode of inhibition by compounds which revealed competitive inhibition for α-amylase and non-competitive inhibition for α-glucosidase. However, in silico study identified several important binding interactions of ligands (synthetic analogues) with the active site of both enzymes.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.

Entities:  

Keywords:  Acarbose; Diabetes; Dual inhibitors; Hyperglycemia; In silico; Kinetic studies; Quinazolinone; α-amylase; α-glucosidase

Mesh:

Substances:

Year:  2021        PMID: 33650031     DOI: 10.1007/s11030-021-10196-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  28 in total

Review 1.  Radicals and oxidative stress in diabetes.

Authors:  I C West
Journal:  Diabet Med       Date:  2000-03       Impact factor: 4.359

2.  The pharmacological profile and initial clinical evaluation of tiacrilast (Ro 22-3747): a new antiallergic agent.

Authors:  A F Welton; A W Dunton; B McGhee
Journal:  Agents Actions       Date:  1986-06

Review 3.  Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

Authors:  E Bonora; M Muggeo
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

4.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

5.  Voglibose: an alpha glucosidase inhibitor.

Authors:  Ajay S Dabhi; Nikita R Bhatt; Mohit J Shah
Journal:  J Clin Diagn Res       Date:  2013-12-15

Review 6.  Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.

Authors:  D Luft; R M Schmülling; M Eggstein
Journal:  Diabetologia       Date:  1978-02       Impact factor: 10.122

7.  Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus.

Authors:  Dieter Neuser; Alice Benson; Andreas Brückner; Ronald B Goldberg; Byron J Hoogwerf; Dieter Petzinna
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 8.  Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.

Authors:  Kishor S Jain; Jitender B Bariwal; Muthu K Kathiravan; Manisha S Phoujdar; Rajkumari S Sahne; Bishram S Chauhan; Anamik K Shah; Mange Ram Yadav
Journal:  Bioorg Med Chem       Date:  2008-03-04       Impact factor: 3.641

9.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

Review 10.  Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.

Authors:  Markolf Hanefeld; Frank Schaper; Carsta Koehler
Journal:  Cardiovasc Drugs Ther       Date:  2008-02-29       Impact factor: 3.727

View more
  1 in total

1.  Antidiabetic, antioxidant, and anti-obesity effects of phenylthio-ethyl benzoate derivatives, and molecular docking study regarding α-amylase enzyme.

Authors:  Nidal Jaradat; Ahmad Khasati; Maram Hawi; Mohammed Hawash; Suhaib Shekfeh; Mohammad Qneibi; Ahmad M Eid; Mohammad Arar; Mohammed T Qaoud
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.